These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 11527547)

  • 21. Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors.
    Wagner JA; Járai Z; Bátkai S; Kunos G
    Eur J Pharmacol; 2001 Jul; 423(2-3):203-10. PubMed ID: 11448486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors.
    Gatley SJ; Gifford AN; Volkow ND; Lan R; Makriyannis A
    Eur J Pharmacol; 1996 Jul; 307(3):331-8. PubMed ID: 8836622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potentiation of anandamide hypotension by the transport inhibitor, AM404.
    Calignano A; La Rana G; Beltramo M; Makriyannis A; Piomelli D
    Eur J Pharmacol; 1997 Oct; 337(1):R1-2. PubMed ID: 9389389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional consequences of the acute administration of the cannabinoid receptor antagonist, SR141716A, in cannabinoid-naive and -tolerant animals: a quantitative 2-[14C]deoxyglucose study.
    Freedland CS; Whitlow CT; Smith HR; Porrino LJ
    Brain Res; 2003 Feb; 962(1-2):169-79. PubMed ID: 12543468
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of opioid and cannabinoid receptor antagonism on orphanin FQ-induced hyperphagia in rats.
    Pietras TA; Rowland NE
    Eur J Pharmacol; 2002 May; 442(3):237-9. PubMed ID: 12065077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity.
    Wallace MJ; Martin BR; DeLorenzo RJ
    Eur J Pharmacol; 2002 Oct; 452(3):295-301. PubMed ID: 12359270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists.
    Lan R; Liu Q; Fan P; Lin S; Fernando SR; McCallion D; Pertwee R; Makriyannis A
    J Med Chem; 1999 Feb; 42(4):769-76. PubMed ID: 10052983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The relationship of in vivo central CB1 receptor occupancy to changes in cortical monoamine release and feeding elicited by CB1 receptor antagonists in rats.
    Need AB; Davis RJ; Alexander-Chacko JT; Eastwood B; Chernet E; Phebus LA; Sindelar DK; Nomikos GG
    Psychopharmacology (Berl); 2006 Jan; 184(1):26-35. PubMed ID: 16328376
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The differential effect of angiotensin II and angiotensin 1-7 on norepinephrine, epinephrine, and dopamine concentrations in rat hypothalamus: the involvement of angiotensin receptors.
    Pawlak R; Napiorkowska-Pawlak D; Takada Y; Urano T; Nagai N; Ihara H; Takada A
    Brain Res Bull; 2001 Apr; 54(6):689-94. PubMed ID: 11403997
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Critical role of the endogenous cannabinoid system in mouse pup suckling and growth.
    Fride E; Ginzburg Y; Breuer A; Bisogno T; Di Marzo V; Mechoulam R
    Eur J Pharmacol; 2001 May; 419(2-3):207-14. PubMed ID: 11426843
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anandamide- and delta9-tetrahydrocannabinol-evoked arachidonic acid mobilization and blockade by SR141716A [N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4 -methyl-1H-pyrazole-3-carboximide hydrochloride].
    Shivachar AC; Martin BR; Ellis EF
    Biochem Pharmacol; 1996 Mar; 51(5):669-76. PubMed ID: 8615904
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual intracellular signaling pathways mediated by the human cannabinoid CB1 receptor.
    Calandra B; Portier M; Kernéis A; Delpech M; Carillon C; Le Fur G; Ferrara P; Shire D
    Eur J Pharmacol; 1999 Jun; 374(3):445-55. PubMed ID: 10422789
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR141716A (rimonabant) and oleoylethanolamide.
    Cani PD; Montoya ML; Neyrinck AM; Delzenne NM; Lambert DM
    Br J Nutr; 2004 Nov; 92(5):757-61. PubMed ID: 15533263
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pre-exposure to the cannabinoid receptor agonist CP 55940 enhances morphine behavioral sensitization and alters morphine self-administration in Lewis rats.
    Norwood CS; Cornish JL; Mallet PE; McGregor IS
    Eur J Pharmacol; 2003 Mar; 465(1-2):105-14. PubMed ID: 12650839
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat.
    Navarro M; Hernández E; Muñoz RM; del Arco I; Villanúa MA; Carrera MR; Rodríguez de Fonseca F
    Neuroreport; 1997 Jan; 8(2):491-6. PubMed ID: 9080435
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased motivation for beer in rats following administration of a cannabinoid CB1 receptor agonist.
    Gallate JE; Saharov T; Mallet PE; McGregor IS
    Eur J Pharmacol; 1999 Apr; 370(3):233-40. PubMed ID: 10334497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of neuropeptide Y on norepinephrine and serotonin metabolism in rat hypothalamus in vivo.
    Shimizu H; Bray GA
    Brain Res Bull; 1989 Jun; 22(6):945-50. PubMed ID: 2477116
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of the 5-HT1D receptor as a presynaptic autoreceptor in the guinea pig.
    Pullar IA; Boot JR; Broadmore RJ; Eyre TA; Cooper J; Sanger GJ; Wedley S; Mitchell SN
    Eur J Pharmacol; 2004 Jun; 493(1-3):85-93. PubMed ID: 15189767
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Boosting effect of morphine on alcohol drinking is suppressed not only by naloxone but also by the cannabinoid CB1 receptor antagonist, SR 141716.
    Vacca G; Serra S; Brunetti G; Carai MA; Gessa GL; Colombo G
    Eur J Pharmacol; 2002 Jun; 445(1-2):55-9. PubMed ID: 12065194
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intraventricular injection of neostigmine increases dopaminergic and noradrenergic nerve activities: hyperglycemic effects and neurotransmitters in the hypothalamus.
    Takahashi A; Ishimaru H; Ikarashi Y; Maruyama Y
    Neurosci Lett; 1993 Jun; 156(1-2):54-6. PubMed ID: 7692365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.